Pioneering Targeted Gene Expression For Cancer and Vaccines
Cancer therapy requires a careful balance, maximizing therapeutic efficacy while minimizing patient toxicity. The ideal cancer treatment would direct therapy selectively to tumor cells while sparing normal cells and tissues. PhageNova Bio has developed a targeted gene delivery vector that accomplishes this goal. The company intends on completing pre-clinical and IND-enabling requirements, manufacturing efforts, and transition quickly into a first-in-human clinical trial.
PhageNova Bio Highlights
Proprietary, first in class, site-specific targeted gene expression technology initially targeting solid tumors and COVID-19
Targeted Gene Expression
Enabled by AAV genomic components within an engineered ligand-directed bacteriophage genome (AAVP)
PNB-001
Lead cancer asset for solid tumors undergoing enabling efforts, pivotal toxicology, and GMP manufacturing as part of an IND initiative
PNB-V01 platform
Broad phage-based vaccination initially targeting COVID-19 undergoing evaluation with proof-of-concept expected 2H21
Intellectual Property
Broad intellectual property protection established; recently filed patent applications
Manufacturing
Scalable, cost-effective, rapid manufacturing capabilities for different targeting motifs and payloads; partnered with leading biologic CMO
Financing
Raised >$8M in equity financing since 2016 and >$10M in federal and private grants.
Catalysts
IND filing of PNB-001 for solid tumors; relaunch of two active INDs for prostate cancer and obesity; near-term data of COVID-19 vaccine strategy; pipeline validation for numerous targets; and new intellectual property grants and filings